• GBM organoids model patient response to CAR T cell therapy December 09, 2024 For the first time, Penn Medicine researchers used lab-grown organoids created from tumors of individuals with glioblastoma to accurately model a patient’s response to CAR T cell therapy in real time.
• Keto diet metabolite may power up CAR T cells to kill cancer December 07, 2024 A simple dietary supplement may provide a new, cost-effective approach to boost CAR T cell function, according to early findings shared at the ASH Annual Meeting.
• Penn Medicine partners with Mark Cuban’s Cost Plus Drugs December 06, 2024 Penn Medicine has partnered with Mark Cuban's Cost Plus Drug Company through its innovative Cost Plus Marketplace in a strategic alliance that will allow Penn Medicine to secure the top 100 most frequently dispensed generic drugs from the company.
• Penn Medicine and IBX Announce New Long-Term Agreement December 03, 2024 The University of Pennsylvania Health System and Independence Blue Cross have reached a long-term agreement on reimbursement rates for a new contract renewal, which would take effect on July 1, 2025.
• Penn Medicine at the 2024 ASH Annual Meeting December 02, 2024 Researchers from the Abramson Cancer Center and Perelman School of Medicine at the University of Pennsylvania will present data on the latest advances in blood cancer and benign hematology research at the ASH Annual Meeting 2024.

Use arrow keys to view news

Use arrow keys to view events